{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:54:50Z","timestamp":1789696490857,"version":"4.0.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To conduct a network meta-analysis comparing the safety and efficacy of gabapentin (GBP), pregabalin (PGB), oxcarbazepine (OXC), and duloxetine (DLX) in treating diabetic peripheral neuropathy (DPN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The study\u2019s eligibility criteria includee randomized controlled trials (RCTs) with a focus on DPN patients receiving GBP, PGB, DLX, or OXC versus placebo. Noncompliant trials with incomplete information and observational studies were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twelve (RCTs) of PGB, 2 of GBP, 3 of DLX, and 1 of OXC met the inclusion criteria. When drugs were compared for efficacy (direct comparison), GBP (Odd\u2019s ratio [OR] = 3.208,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) was most effective followed by OXC (OR = 2.4,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0248), DLX (OR = 2.346,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and PGB (OR = 2.161,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). When drugs were compared for withdrawal due to adverse\n                      <jats:italic toggle=\"yes\">drug<\/jats:italic>\n                      reaction (ADR) (direct comparison), GBP (OR = 1.3818,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.766) was safest followed by PGB (OR = 2.16,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), DLX (OR = 2.469,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and OXC (OR = 4.4967,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). Indirect comparison was done for efficacy, DLX was statistically significant than PGB and OXC (DLX vs. PGB,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03; DLX vs. OXC,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02). When indirect comparison was done for patient withdrawal due to ADR, OXC was worst (GBP vs. OXC,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0001; PGB vs. OXC,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007; DLX vs. OXC,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.015). When drugs were compared for individual ADRs (direct comparison), dizziness was most commonly seen with OXC (OR = 9.6535,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 1.8425), headache with OXC (OR = 3.8686,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006), somnolence with PGB (OR = 5.189,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and nausea with DLX (OR = 3.264,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). GBP was most effective and safest drug followed by OXC &gt; DLX &gt; PGB for efficacy and PGB &gt; DLX &gt; OXC for safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In evaluating medications for DPN against placebo, GBP and OXC demonstrated the highest effectiveness while maintaining a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/picr.picr_218_23","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T10:00:37Z","timestamp":1720605637000},"page":"202-208","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comparative efficacy and safety of gabapentin, pregabalin, oxcarbazepine, and duloxetine in diabetic peripheral neuropathy: A network meta-analysis"],"prefix":"10.4103","volume":"15","author":[{"given":"Karan Bhavesh","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Smt.NHL MMC, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devang A.","family":"Rana","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Smt.NHL MMC, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash Dharmendra","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Smt.NHL MMC, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya Deepak","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Smt.NHL MMC, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"R1-20241011","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11892-019-1212-8","article-title":"Epidemiology of peripheral neuropathy and lower extremity disease in diabetes","volume":"19","author":"Hicks","year":"2019","journal-title":"Curr Diab Rep"},{"key":"R2-20241011","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/IJGM.S273807","article-title":"Prevalence and Risk Factors for Diabetic Peripheral Neuropathy Among Saudi Hospitalized Diabetic Patients:A Nested Case-Control Study","volume":"13","author":"Aleidan","year":"2020","journal-title":"Int J Gen Med"},{"key":"R4-20241011","doi-asserted-by":"crossref","first-page":"e00205","DOI":"10.1002\/prp2.205","article-title":"Mechanisms of the gabapentinoids and \u03b12 \u03b4-1 calcium channel subunit in neuropathic pain","volume":"4","author":"Patel","year":"2016","journal-title":"Pharmacol Res Perspect"},{"key":"R5-20241011","first-page":"CD007963","article-title":"Oxcarbazepine for neuropathic pain","volume":"12","author":"Zhou","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-20241011","first-page":"833","article-title":"Review of duloxetine in the management of diabetic peripheral neuropathic pain","volume":"3","author":"Smith","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"R7-20241011","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/jnnp.66.2.251","article-title":"Gabapentin in the treatment of painful diabetic neuropathy:A placebo controlled, double blind, crossover trial","volume":"66","author":"Gorson","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R8-20241011","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","article-title":"Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus:a randomized controlled trial","volume":"280","author":"Backonja","year":"1998","journal-title":"JAMA"},{"key":"R9-20241011","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","article-title":"Pregabalin for relief of neuropathic pain associated with diabetic neuropathy:a randomized, double-blind study","volume":"12","author":"T\u00f6lle","year":"2008","journal-title":"Eur J Pain"},{"key":"R10-20241011","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","article-title":"Pregabalin relieves symptoms of painful diabetic neuropathy:A randomized controlled trial","volume":"63","author":"Lesser","year":"2004","journal-title":"Neurology"},{"key":"R11-20241011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2377-8-33","article-title":"Efficacy and safety of pregabalin 600 mg\/d for treating painful diabetic peripheral neuropathy:A double-blind placebo-controlled trial","volume":"8","author":"Arezzo","year":"2008","journal-title":"BMC Neurol"},{"key":"R12-20241011","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","article-title":"Pregabalin for the treatment of painful diabetic peripheral neuropathy:a double-blind, placebo-controlled trial","volume":"110","author":"Rosenstock","year":"2004","journal-title":"Pain"},{"key":"R13-20241011","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","article-title":"Relief of painful diabetic peripheral neuropathy with pregabalin:A randomized, placebo-controlled trial","volume":"6","author":"Richter","year":"2005","journal-title":"J Pain"},{"key":"R14-20241011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1464-5491.2010.03152.x","article-title":"Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy:A 14 week, randomized, double-blind, placebo-controlled trial","volume":"28","author":"Satoh","year":"2011","journal-title":"Diabet Med"},{"key":"R15-20241011","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","article-title":"Pregabalin for re-lief of neuropathic pain associated with diabetic neuropathy:A randomized double-blind study","volume":"12","author":"Tolle","year":"2008","journal-title":"Eur J Pain"},{"key":"R16-20241011","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/dc07-2105","article-title":"Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy:Findings from seven randomized, controlled trials across a range of doses","volume":"31","author":"Freeman","year":"2008","journal-title":"Diabetes Care"},{"key":"R17-20241011","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","article-title":"A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain","volume":"67","author":"Wernicke","year":"2006","journal-title":"Neurology"},{"key":"R18-20241011","doi-asserted-by":"crossref","first-page":"10918","DOI":"10.1016\/j.pain.2005.03.029","article-title":"Duloxetine versus placebo in patients with painful diabetic neuropathy","volume":"116","author":"Goldstein","year":"2005","journal-title":"Pain"},{"key":"R19-20241011","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","article-title":"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain","volume":"6","author":"Raskin","year":"2005","journal-title":"Pain Med"},{"key":"R20-20241011","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4065\/mcp.2010.0681","article-title":"Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin:An open-label, randomized, noninferiority comparison","volume":"86","author":"Tanenberg","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"R21-20241011","doi-asserted-by":"crossref","first-page":"4084420","DOI":"10.1155\/2022\/4084420","article-title":"Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain:A Meta-Analysis","volume":"2022","author":"Jiang","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"R22-20241011","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.seizure.2010.12.011","article-title":"Gastrointestinal adverse effects of antiepileptic drugs in intractable epileptic patients","volume":"20","author":"Jahromi","year":"2011","journal-title":"Seizure"}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_218_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:26:11Z","timestamp":1787837171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_218_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/picr.picr_218_23","relation":{},"ISSN":["2229-3485","2229-5488"],"issn-type":[{"value":"2229-3485","type":"print"},{"value":"2229-5488","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"2023-08-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}